Yuichiro Kaneko
Overview
Explore the profile of Yuichiro Kaneko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
427
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mizuno-Onishi Y, Igarashi T, Uramoto K, Kaneko Y, Nagaoka N, Yoshida T, et al.
Retina
. 2024 Nov;
45(3):464-471.
PMID: 39602699
Purpose: The natural course of the visual acuity in eyes with myopic macular neovascularization is poor. Intravitreal injections of anti-vascular endothelial growth factor agents have demonstrated safety and efficacy in...
2.
Tanaka Y, Takeuchi T, Morita Y, Kaneko Y, Terada W
Mod Rheumatol
. 2023 Dec;
34(5):918-926.
PMID: 38103258
Objectives: This post hoc analysis of the RAJ2 study assessed long-term safety and effectiveness of peficitinib 100 mg/day for treatment of rheumatoid arthritis. Methods: Eligible patients previously completed two Phase...
3.
Takeuchi T, Tanaka Y, Morita Y, Kato D, Kaneko Y, Terada W
Mod Rheumatol
. 2023 Oct;
34(5):947-953.
PMID: 37902304
Objectives: The current study assesses the utility of matrix metalloprotease-3 (MMP-3) as a biomarker for joint damage in patients with rheumatoid arthritis receiving peficitinib. Methods: Rheumatoid arthritis patients with inadequate...
4.
Kaneko Y, Morita S
J Biopharm Stat
. 2023 Aug;
34(5):626-645.
PMID: 37585719
The delayed treatment effect, which manifests as a separation of survival curves after a change point, has often been observed in immunotherapy clinical trials. A late effect of this kind...
5.
Tanaka Y, Takeuchi T, Morita Y, Kato D, Kaneko Y, Terada W
Mod Rheumatol
. 2023 Jun;
34(3):453-465.
PMID: 37319017
Objective: We evaluated remission rates and their relationship with baseline characteristics in patients with rheumatoid arthritis treated with the oral Janus kinase inhibitor peficitinib. Methods: This post hoc analysis of...
6.
Gao X, He X, Oshima H, Miyatake D, Otsuka Y, Kato K, et al.
Drug Des Devel Ther
. 2022 May;
16:1365-1381.
PMID: 35586186
Objective: To investigate the pharmacokinetics and safety of peficitinib (Janus kinase inhibitor for the treatment of rheumatoid arthritis) in healthy Chinese subjects following single and multiple doses. Methods: This open-label,...
7.
Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Izutsu H, et al.
Mod Rheumatol
. 2022 Mar;
33(1):73-80.
PMID: 35267027
Objective: To determine the efficacy of peficitinib in reducing joint damage and predictive factors affecting treatment response in Japanese patients with rheumatoid arthritis. Methods: This post hoc analysis used data...
8.
Du R, Xie S, Fang Y, Hagino S, Yamamoto S, Moriyama M, et al.
Asia Pac J Ophthalmol (Phila)
. 2021 Dec;
11(3):227-236.
PMID: 34937047
Purpose: It is common for physicians to be uncertain when examining some images. Models trained with human uncertainty could be a help for physicians in diagnosing pathologic myopia. Design: This...
9.
Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Izutsu H, et al.
Mod Rheumatol
. 2021 Dec;
32(4):708-717.
PMID: 34918131
Objective: To analyse serious infection (SI) and herpes zoster-related disease (HZD) during long-term treatment of rheumatoid arthritis with the oral Janus kinase inhibitor, peficitinib (ASP015K). Methods: This was a post...
10.
Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Miyatake D
Mod Rheumatol
. 2021 Dec;
32(4):696-707.
PMID: 34850095
Objectives: To evaluate peficitinib efficacy and safety in Asian patients with rheumatoid arthritis (RA), stratified by age (≥20-<50, ≥50-<65, and ≥65 years). Methods: Efficacy data from two Phase 3 studies...